The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Muscle-invasive bladder cancer | A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) (KEYNOTE-992) | KEYNOTE-992 | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE |
| Muscle-invasive bladder cancer | A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) (KEYNOTE-992) | KEYNOTE-992 | Pulau Pinang Hospital | DR SOO HOO HWOEI FEN |
+604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic breast cancer | A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer | RIGHT CHOICE | Kuala Lumpur Hospital (HKL) | DR MALWINDER SINGH SANDHU | +603 – 2615 5555, Ext. 1782 / 1783 |
CLICK HERE |
| Metastatic breast cancer | A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer | RIGHT CHOICE | Sarawak General Hospital | DR VOON PEI JYE | +608 – 2276 820 | CLICK HERE |
| Metastatic breast cancer | A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer | RIGHT CHOICE | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| Metastatic breast cancer | A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer | RIGHT CHOICE | Hospital Wanita dan Kanak-Kanak Sabah | DR FLORA CHONG LI TZE | +608 – 8522 600, Ext. 2272 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic adenocarcinoma and squamous cell carcinoma of the esophagus | A phase III randomized open-label study of single agent pembrolizumab vs physicians’ choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy (KEYNOTE-181) | MK3475-181 | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | GLOW | Kuala Lumpur Hospital (HKL) | DR NOOR ZAFIFAH BINTI ZAKARIA | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | GLOW | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | GLOW | Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | GLOW | Hospital Wanita dan Kanak-Kanak Sabah | DR SUCHARIT PONGPRAKYUN | +608 – 8522 600, Ext. 2272 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Head and Neck Squamous Cell Carcinoma | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) | KO-TIP-007 | National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK | +603 – 88925555, Ext. 4168 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Hepatocellular Carcinoma | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | KEYNOTE-937 | National Cancer Institute (IKN) | DR WONG YOKE FUI, Florence | +603 – 8892 5555, Ext. 4168 | CLICK HERE |
| Hepatocellular Carcinoma | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | KEYNOTE-937 | Sarawak General Hospital | DR LIM YUEH NI | +608 – 2276 820 | CLICK HERE |
| Unresectable biliary tract carcinoma | A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma | KEYNOTE-966 | Kuala Lumpur Hospital (HKL) | DR VAISHNAVI A/P JEYASINGAM | +603 – 2615 5555, Ext 1620 / 1144 |
CLICK HERE |
| Unresectable biliary tract carcinoma | A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma | KEYNOTE-966 | National Cancer Institute (IKN) | DR TAN CHIH KIANG | +603 – 8892 5418 / +603 – 8892 5555, Ext. 4168 |
CLICK HERE |
| Unresectable biliary tract carcinoma | A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma | KEYNOTE-966 | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE |
| Unresectable biliary tract carcinoma | A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma | KEYNOTE-966 | Pulau Pinang Hospital | DR TAN AI LIAN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Non-small cell lung cancer | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | CANOPY A | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Non-small cell lung cancer | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | CANOPY A | Pulau Pinang Hospital | DR TAN AI LIAN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Non-small cell lung cancer | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | CANOPY A | Sarawak General Hospital | DR SYADWA BINTI ABDUL SHUKOR | +608 – 2276 820 | CLICK HERE |
| Metastatic non-small cell lung cancer | A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 >= 50% | CINC280I12201 | Sarawak General Hospital | DR SYADWA BINTI ABDUL SHUKOR | +608 – 2276 820 | CLICK HERE |
| Non-Small Cell Lung Cancer | A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy | MS200095-0031 | Pantai Hospital Kuala Lumpur | DR THO LYE MUN | +603 – 2296 0800 | CLICK HERE |
| Non-Small Cell Lung Cancer | A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy | MS200095-0031 | Sarawak General Hospital | DR SYADWA BINTI ABDUL SHUKOR | +608 – 2276 820 | CLICK HERE |
| Non-Small Cell Lung Cancer | A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy | MS200095-0031 | Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN | +609 – 5572 922 | CLICK HERE |
| Non-Small Cell Lung Cancer | A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy | MS200095-0031 | Pulau Pinang Hospital | DR IRFHAN ALI B HYDER ALI | +604 – 2225 767 / 2225 762 / 2225 766 |
CLICK HERE |
| Non-squamous Non-small Cell Lung Cancer | A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety,Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer | SAMSON-II | Raja Perempuan Zainab II Hospital, Kota Bharu | DR AZZA BINTI OMAR | +609 – 7452 636 | |
| Non-squamous Non-small Cell Lung Cancer | A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety,Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer | SAMSON-II | Pulau Pinang Hospital | DR IRFHAN ALI B HYDER ALI | +604 – 2225 767 / 2225 762 / 2225 766 |
|
| Non-squamous Non-small Cell Lung Cancer | A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety,Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer | SAMSON-II | Kuala Lumpur Hospital (HKL) | DR PRATHEPAMALAR A/P YEHGAMBARAM | +603 – 2615 5555, Ext. 1620 / 1144 |
|
| Metastatic Non-Small Cell Lung Cancer | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 61186372NSC3001 (Papillon) | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| Metastatic Non-Small Cell Lung Cancer | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 61186372NSC3001 (Papillon) | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE |
| Metastatic Non-Small Cell Lung Cancer | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 61186372NSC3001 (Papillon) | Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Metastatic Non-Small Cell Lung Cancer | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | 73841937NSC3003 (Mariposa) | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| Metastatic Non-Small Cell Lung Cancer | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | 73841937NSC3003 (Mariposa) | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE |
| Metastatic Non-Small Cell Lung Cancer | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | 73841937NSC3003 (Mariposa) | Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN | +609 – 5572 922 | CLICK HERE |
| Metastatic Non-Small Cell Lung Cancer | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | 73841937NSC3003 (Mariposa) | Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Metastatic non-small cell lung cancer | A Single-Arm, Open-Label, Phase 2 Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation | ATORG-003 | Sarawak General Hospital | DR LIM YUEH NI | +608 – 2276 820 | CLICK HERE |
| Non-Small Cell Lung Cancer (Stage III) | Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) | LAURA | Kuala Lumpur Hospital (HKL) | DR IBTISAM MUHAMAD NOR | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer | A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) | INCMGA0012-304 | Tengku Ampuan Afzan Hospital, Kuantan | DR AISHAH BINTI IBRAHIM | +609 – 5572 922 | CLICK HERE |
| Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer | A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) | INCMGA0012-304 | Sarawak General Hospital | DR HENG FOOK YEW | +608 – 2276 820 | CLICK HERE |
| Non-small Cell Lung Cancer | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/ Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) | MK-3475-671 | Sarawak General Hospital | DR HENG FOOK YEW | +608 – 2276 820 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Hospital Wanita dan Kanak-Kanak Sabah | DR SOON RUEY | +608 – 8522 600, Ext. 2272 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Miri Hospital | DR HARRIS ROLAND DEMONG | +608 – 5413 673, Ext. 520 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Selayang Hospital | DR NOR ELYANA NOORDIN | +603 – 6126 3333, Ext. 4318 / 4314 / 4181 |
CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Seberang Jaya Hospital | DR SALINA BINTI SANY | +604 – 3827 333, Ext: 511 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Sibu Hospital | DR SII LEH PING | + 608 – 4343 333 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Sultan Ismail Hospital, Johor Bahru | DR NOR HIDAYAH BT YAYANTO | +607 – 3565 155 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Raja Perempuan Zainab II Hospital, Kota Bharu | DR NIK AHMAD BIN NIK ABDULLAH | +609 – 7452 636 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Sarawak General Hospital | DR SIM WEE WEE | +608 – 2276 820 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Taiping Hospital | DR NORLIA BINTI MOHAMAD | +605 – 8204 029 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Raja Permaisuri Bainun Hospital, Ipoh | DR LEE SAW JOO | +605 – 2085 146 | CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Ampang Hospital | DR YONG CHEE MENG | +603 – 4289 6559 / 6560 |
CLICK HERE |
| Ovarian Cancer | Clinical Validation of the Venn Ovarian Cancer Liquid Biopsy: VOCAL Study | OVACA-001 | Tengku Ampuan Afzan Hospital, Kuantan | DR YONG SOON LEONG | +609 – 5572 922 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastic Prostate Cancer | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer | MAGNITUDE | Kuala Lumpur Hospital (HKL) | DR VIJAYAN MANOGRAN @ MANOHARAN | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| Metastic Prostate Cancer | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer | MAGNITUDE | Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Metastic Prostate Cancer | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer | MAGNITUDE | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| Metastic Prostate Cancer | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer | MAGNITUDE | Hospital Wanita dan Kanak-Kanak Sabah | DR FLORA CHONG LI TZE | +608 – 8522 600 Ext. 2272 | CLICK HERE |
| Metastatic Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 64091742PCR0002 | Sarawak General Hospital | DR HADI BIN AB.JALIL | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 / 276 820 |
CLICK HERE |
| Metastatic Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 64091742PCR0002 | Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Metastatic Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 64091742PCR0002 | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE |
| Metastatic Castration-Sensitive Prostate Cancer | Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | AMPLITUDE | Sarawak General Hospital | DR HADI BIN AB.JALIL | +608 – 227 6666 / 6035 / 276 820 |
CLICK HERE |
| Metastatic Castration-Sensitive Prostate Cancer | Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | AMPLITUDE | National Cancer Institute (IKN) | DR ARNIL GEORGE SIRIMANNE | +603 – 8892 5555, Ext. 4168 | CLICK HERE |
| Metastatic Castration-Sensitive Prostate Cancer | Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | AMPLITUDE | Pulau Pinang Hospital | DR FONG CHIN HENG | +604 – 2225 767 / 2225 762 / 2225 766 |
CLICK HERE |
| Metastatic Castration-Sensitive Prostate Cancer | Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | AMPLITUDE | Kuala Lumpur Hospital (HKL) | DR PRATHEPAMALAR A/P YEHGAMBARAM | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
The information above was last updated on 20 May 2021.
Source: http://clinicalresearch.my/
Links are from CLINICALTRIAL.GOV
